Heart Failure
Wegovy beneficial in HFpEF regardless of diuretic use, cuts need for diuretics
In patients with the obesity phenotype of HF with preserved ejection, semaglutide 2.4 mg improved HF-related symptoms and physical limitations vs. placebo regardless of diuretic use, according to new data from the STEP-HFpEF trials.
Top in cardiology: Anger may raise CVD risk; cardiovascular-kidney-metabolic syndrome
A laboratory-based, randomized controlled experimental study revealed that anger can negatively impact vascular endothelial health and function, potentially raising heart disease risk.
Findings may help reduce cardiotoxicity of ponatinib for chronic myeloid leukemia
Researchers have discovered the mechanisms by which the chemotherapy drug ponatinib harms the heart.
US heart failure deaths in 2021 reached levels not seen since 1999
Decades of declining heart failure mortality in the U.S. has reversed, and exceeded rates recorded more than 20 years ago, according to overall population-level data published in JAMA Cardiology.
FDA-cleared AI app for point-of-care diagnosis of heart failure launched
Exo announced the launch of its FDA-cleared AI imaging applications for the diagnosis of heart failure on its handheld ultrasound device.
Part of the Healio Network
Sodium-Glucose Transporter 2 (SGLT2) Inhibitors Topic Review
As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a]
E-cigarette use could raise heart failure risk up to 19%
ATLANTA — Individuals with a history of e-cigarette use may have increased risk for incident heart failure, regardless of concomitant cigarette, cigar, hookah or smokeless cigarette use, a speaker reported.
LVAD obstruction linked to 14 deaths; FDA designates recall as class I
Abbott/Thoratec Corp. issued a recall of two of its left ventricular assist devices due to risk for obstruction from the long-term buildup of biological material during use.
Phone calls improve heart failure medical therapy for patients from Navajo Nation
ATLANTA — A phone-based telehealth model improved rates of guideline-directed classes of HF drugs filled at the pharmacy at 30 days among adults with HF with reduced ejection fraction in Navajo Nation, where access to care is limited.
Top in cardiology: Revised Lp(a) recommendations; FDA OKs AI-based algorithm to detect HF
The National Lipid Association updated its guidelines concerning the use of lipoprotein(a) in clinical practice, advising that there is a continuous relationship between a patient’s cardiovascular risk and their levels of Lp(a).